IBDEI0MN ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10557,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10557,1,3,0)
 ;;=3^Hypertension,Essential
 ;;^UTILITY(U,$J,358.3,10557,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,10557,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,10558,0)
 ;;=L71.9^^44^507^19
 ;;^UTILITY(U,$J,358.3,10558,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10558,1,3,0)
 ;;=3^Rosacea,Unspec
 ;;^UTILITY(U,$J,358.3,10558,1,4,0)
 ;;=4^L71.9
 ;;^UTILITY(U,$J,358.3,10558,2)
 ;;=^5009276
 ;;^UTILITY(U,$J,358.3,10559,0)
 ;;=L71.8^^44^507^18
 ;;^UTILITY(U,$J,358.3,10559,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10559,1,3,0)
 ;;=3^Rosacea NEC
 ;;^UTILITY(U,$J,358.3,10559,1,4,0)
 ;;=4^L71.8
 ;;^UTILITY(U,$J,358.3,10559,2)
 ;;=^5009275
 ;;^UTILITY(U,$J,358.3,10560,0)
 ;;=L71.1^^44^507^17
 ;;^UTILITY(U,$J,358.3,10560,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10560,1,3,0)
 ;;=3^Rhinophyma
 ;;^UTILITY(U,$J,358.3,10560,1,4,0)
 ;;=4^L71.1
 ;;^UTILITY(U,$J,358.3,10560,2)
 ;;=^106083
 ;;^UTILITY(U,$J,358.3,10561,0)
 ;;=S05.31XA^^44^507^13
 ;;^UTILITY(U,$J,358.3,10561,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10561,1,3,0)
 ;;=3^Ocular Laceration Right Eye w/o Prolapse/Loss of Intraoc Tissue,Init Encntr
 ;;^UTILITY(U,$J,358.3,10561,1,4,0)
 ;;=4^S05.31XA
 ;;^UTILITY(U,$J,358.3,10561,2)
 ;;=^5020606
 ;;^UTILITY(U,$J,358.3,10562,0)
 ;;=S05.32XA^^44^507^12
 ;;^UTILITY(U,$J,358.3,10562,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10562,1,3,0)
 ;;=3^Ocular Laceration Left Eye w/o Prolapse/Loss of Intraoc Tissue,Init Encntr
 ;;^UTILITY(U,$J,358.3,10562,1,4,0)
 ;;=4^S05.32XA
 ;;^UTILITY(U,$J,358.3,10562,2)
 ;;=^5020609
 ;;^UTILITY(U,$J,358.3,10563,0)
 ;;=Z21.^^44^507^2
 ;;^UTILITY(U,$J,358.3,10563,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10563,1,3,0)
 ;;=3^Asymptomatic HIV Infection Status
 ;;^UTILITY(U,$J,358.3,10563,1,4,0)
 ;;=4^Z21.
 ;;^UTILITY(U,$J,358.3,10563,2)
 ;;=^5062777
 ;;^UTILITY(U,$J,358.3,10564,0)
 ;;=Z83.511^^44^507^6
 ;;^UTILITY(U,$J,358.3,10564,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10564,1,3,0)
 ;;=3^Family Hx of Glaucoma
 ;;^UTILITY(U,$J,358.3,10564,1,4,0)
 ;;=4^Z83.511
 ;;^UTILITY(U,$J,358.3,10564,2)
 ;;=^5063382
 ;;^UTILITY(U,$J,358.3,10565,0)
 ;;=Z83.518^^44^507^5
 ;;^UTILITY(U,$J,358.3,10565,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10565,1,3,0)
 ;;=3^Family Hx of Eye Disorder NEC
 ;;^UTILITY(U,$J,358.3,10565,1,4,0)
 ;;=4^Z83.518
 ;;^UTILITY(U,$J,358.3,10565,2)
 ;;=^5063383
 ;;^UTILITY(U,$J,358.3,10566,0)
 ;;=Z79.899^^44^507^10
 ;;^UTILITY(U,$J,358.3,10566,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10566,1,3,0)
 ;;=3^Long Term Current Drug Therapy NEC
 ;;^UTILITY(U,$J,358.3,10566,1,4,0)
 ;;=4^Z79.899
 ;;^UTILITY(U,$J,358.3,10566,2)
 ;;=^5063343
 ;;^UTILITY(U,$J,358.3,10567,0)
 ;;=Z01.00^^44^507^4
 ;;^UTILITY(U,$J,358.3,10567,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10567,1,3,0)
 ;;=3^Eye/Vision Exam w/o Abnormal Findings
 ;;^UTILITY(U,$J,358.3,10567,1,4,0)
 ;;=4^Z01.00
 ;;^UTILITY(U,$J,358.3,10567,2)
 ;;=^5062612
 ;;^UTILITY(U,$J,358.3,10568,0)
 ;;=Z01.01^^44^507^3
 ;;^UTILITY(U,$J,358.3,10568,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10568,1,3,0)
 ;;=3^Eye/Vision Exam w/ Abnormal Findings
 ;;^UTILITY(U,$J,358.3,10568,1,4,0)
 ;;=4^Z01.01
 ;;^UTILITY(U,$J,358.3,10568,2)
 ;;=^5062613
 ;;^UTILITY(U,$J,358.3,10569,0)
 ;;=E05.90^^44^507^21
 ;;^UTILITY(U,$J,358.3,10569,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10569,1,3,0)
 ;;=3^Thyrotoxicosis,Unspec
 ;;^UTILITY(U,$J,358.3,10569,1,4,0)
 ;;=4^E05.90
 ;;^UTILITY(U,$J,358.3,10569,2)
 ;;=^5002492
 ;;^UTILITY(U,$J,358.3,10570,0)
 ;;=99201^^45^508^1
